Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 18844464)

1.

Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.

Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Alvarez N, Moltó J, Gómez G, Clotet B.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1301-7. doi: 10.1089/aid.2007.0310.

PMID:
18844464
2.

The prevalence and incidence of neurocognitive impairment in the HAART era.

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ.

AIDS. 2007 Sep 12;21(14):1915-21.

PMID:
17721099
3.

Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort.

Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P.

J Neurovirol. 2005 Jul;11(3):265-73.

PMID:
16036806
4.

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.

Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I; CHARTER Group.

AIDS. 2011 Sep 10;25(14):1747-51. doi: 10.1097/QAD.0b013e32834a40cd.

5.

Neurocognitive function in HIV-infected patients with low weight and weight loss.

Dolan S, Montagno A, Wilkie S, Aliabadi N, Sullivan M, Zahka N, Sherman JC, Grinspoon S.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):155-64.

PMID:
14526204
6.

Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Muñoz-Moreno JA, Fumaz CR, Prats A, Ferrer MJ, Negredo E, Pérez-Alvarez N, Moltó J, Gómez G, Garolera M, Clotet B.

J Neurovirol. 2010 May;16(3):208-18. doi: 10.3109/13550281003767710.

PMID:
20450380
7.

Neurocognitive function profile in HIV-infected school-age children.

Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP.

Eur J Paediatr Neurol. 2008 Jul;12(4):290-7. Epub 2007 Oct 18.

PMID:
17950012
8.

Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.

Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, Steenhoff A.

J Int AIDS Soc. 2010 Apr 20;13:15. doi: 10.1186/1758-2652-13-15.

9.

Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts.

Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, Rosenthal PJ, Dorsey G, Achan J, Akello C, Kamya MR, Wong JK.

Clin Infect Dis. 2012 Apr;54(7):1001-9. doi: 10.1093/cid/cir1037. Epub 2012 Feb 4.

10.

Symptomatic distal sensory polyneuropathy in HIV after age 50.

Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, Shikuma CM, Valcour VG.

Neurology. 2004 Apr 27;62(8):1378-83.

PMID:
15111677
11.

A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen.

Muñoz-Moreno JA, Prats A, Pérez-Álvarez N, Fumaz CR, Garolera M, Doval E, Negredo E, Ferrer MJ, Clotet B; NEU Study Group.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):585-92. doi: 10.1097/QAI.0b013e31829e1408.

PMID:
24135776
12.

Neurocognitive symptoms and impairment in an HIV community clinic.

Kim DH, Jewison DL, Milner GR, Rourke SB, Gill MJ, Power C.

Can J Neurol Sci. 2001 Aug;28(3):228-31.

PMID:
11513341
13.

Reaction time in patients with HIV/AIDS and correlation with CD4 count: a case-control study.

Ogunrin AO, Odiase FE, Ogunniyi A.

Trans R Soc Trop Med Hyg. 2007 May;101(5):517-22. Epub 2007 Jan 23.

PMID:
17254620
14.

Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.

Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C.

HIV Med. 2009 Apr;10(4):246-52. doi: 10.1111/j.1468-1293.2008.00679.x. Epub 2009 Jan 23.

PMID:
19187172
15.

The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.

Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E.

Biomed Pharmacother. 2009 Sep;63(8):561-5. doi: 10.1016/j.biopha.2008.09.015. Epub 2008 Nov 5.

PMID:
19026516
16.

Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting.

Mangclaviraj S, Kerr SJ, Chaithongwongwatthana S, Ananworanich J, Hirschel B, Emery S, Cooper DA, Chotnopparatpattara P, Ruxrungtham K, Phanuphak P.

Int J STD AIDS. 2008 Aug;19(8):529-32. doi: 10.1258/ijsa.2007.007222.

PMID:
18663038
17.
18.

Neurological complications in patients with HIV/AIDS.

Bolokadze N, Gabunia P, Ezugbaia M, Gatserelia L, Khechiashvili G.

Georgian Med News. 2008 Dec;(165):34-8.

PMID:
19124914
19.

Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study.

Pathai S, Deshpande A, Gilbert C, Lawn SD.

BMC Infect Dis. 2009 Sep 23;9:158. doi: 10.1186/1471-2334-9-158.

20.

Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history.

Wallace MR, Heaton RK, McCutchan JA, Malone JL, Velin R, Nelson J, Miller LK, Weiss PJ, Oldfield EC 3rd, Grant I.

Sex Transm Dis. 1997 Aug;24(7):398-401.

PMID:
9263360
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk